Roche continues good momentum into 2025 with a 6% (CER) sales growth in the first quarter. For more details on our performance, click here ➡️ https://spkl.io/6046fI9l2
Info
Roche ist ein globales Unternehmen mit Vorreiterrolle in der Erforschung und Entwicklung von Medikamenten und Diagnostika und ist darauf fokussiert, Menschen durch wissenschaftlichen Fortschritt ein besseres, längeres Leben zu ermöglichen. Dank der Kombination von Pharma und Diagnostika unter einem Dach ist Roche führend in der personalisierten Medizin - einer Strategie mit dem Ziel, jeder Patientin und jedem Patienten die bestmögliche Behandlung zukommen zu lassen. Roche ist das grösste Biotech-Unternehmen weltweit mit differenzierten Medikamenten für die Onkologie, Immunologie, Infektionskrankheiten, Augenheilkunde und Erkrankungen des Zentralnervensystems. Roche ist auch der bedeutendste Anbieter von In-vitro-Diagnostika und gewebebasierten Krebstests und ein Pionier im Diabetesmanagement. Seit der Gründung im Jahr 1896 erforscht Roche bessere Wege, um Krankheiten zu verhindern, zu erkennen und zu behandeln und leistet einen nachhaltigen Beitrag zur gesellschaftlichen Entwicklung. Zum Ziel des Unternehmens gehört es durch Kooperationen mit allen relevanten Partnern den Zugang von Patienten zu medizinischen Innovationen zu verbessern. Auf der Liste der unentbehrlichen Arzneimittel der Weltgesundheitsorganisation stehen heute 30 von Roche entwickelte Medikamente, darunter lebensrettende Antibiotika, Malariamittel und Krebsmedikamente. Ausgezeichnet wurde Roche zudem bereits das neunte Jahr in Folge als das nachhaltigste Unternehmen innerhalb der Pharma-, Biotechnologie- und Life-Sciences-Branche im Dow Jones Sustainability Index. Die Roche-Gruppe mit Hauptsitz in Basel, Schweiz ist in über 100 Ländern tätig und beschäftigte 2017 weltweit rund 94 000 Mitarbeiterinnen und Mitarbeiter. Im Jahr 2017 investierte Roche CHF 10,4 Milliarden in Forschung und Entwicklung und erzielte einen Umsatz von CHF 53,3 Milliarden. Genentech in den USA gehört vollständig zur Roche-Gruppe. Roche ist Mehrheitsaktionär von Chugai Pharmaceutical, Japan. Weitere Informationen finden Sie unter www.roche.com/careers #Roche #Biotechnology #Pharmaceuticals #Diagnostics #Healthcare #PersonalizedHealthcare #GreatPlaceToWork #Innovation
- Website
-
http://www.roche.com/
Externer Link zu Roche
- Branche
- Biotechnologieforschung
- Größe
- 10.001+ Beschäftigte
- Hauptsitz
- Switzerland 🇨🇭
- Art
- Kapitalgesellschaft (AG, GmbH, UG etc.)
- Spezialgebiete
- biotechnology, innovation, personalized healthcare, great place to work, diagnostics, pharmaceuticals, research, healthcare, personalised healthcare, diabetes care, genomics, healthcare technology, big data und Science
Orte
Beschäftigte von Roche
Updates
-
Did you know that mass spectrometry can transform vitamin D testing, enabling more personalized treatment plans? Precise vitamin D testing can be crucial for newborns, kidney patients and those in critical care. Discover how advancements in mass spectrometry can enhance diagnostics and patient care. https://lnkd.in/dqB4eWHu #massspectrometry #innovation #diagnostics #RocheMassSpec
-
Roche hat dies direkt geteilt
“Antibiotics have saved billions of lives; our children, our parents, our family, our friends, new antibiotics bring potential to save billions more” - Michael Lobritz, MD, PhD, VP and Global Head of Infectious Diseases, Therapeutic Area, Roche. At Roche, our mission transcends science; it’s about people, their stories, and the future, as Michael states. We are steadfast in our commitment to combat antimicrobial resistance (AMR) and lead the way towards a healthier world. Here’s how we’re making a heartfelt difference: - We are at the forefront of scientific collaboration, focusing on novel diagnostic technologies and treatments to target resistant bacteria. - By driving coordinated action with a broad range of partners, we are tackling AMR from multiple fronts and ensuring a unified response. - By working together to improve patients' access to the latest innovations. Through these efforts, Roche is dedicated to preserving the effectiveness of antibiotics and safeguarding global health for future generations. Click here to learn more: https://lnkd.in/dWnC_pf7 #AMR #AntibioticResistance #RocheAMR
-
Roche hat dies direkt geteilt
Discover Susagna Padrissa Altes' journey of curiosity and resilience. As a child, she often felt out of place, searching for a space where she could truly belong. That space revealed itself in the realm of starting her career at Roche and using her passion for science along with her skills to build community and help people coming together, allowing them to thrive to build a healthier future for everyone and generations to come. 🌟Let’s build a healthier future, together. Start your journey with us. Learn more: https://lnkd.in/d-Rg_Y6d https://lnkd.in/d77ZE5Hw
Finding Belonging in Science: Susagna's Journey
https://www.youtube.com/
-
“Antibiotics have saved billions of lives; our children, our parents, our family, our friends, new antibiotics bring potential to save billions more” - Michael Lobritz, MD, PhD, VP and Global Head of Infectious Diseases, Therapeutic Area, Roche. At Roche, our mission transcends science; it’s about people, their stories, and the future, as Michael states. We are steadfast in our commitment to combat antimicrobial resistance (AMR) and lead the way towards a healthier world. Here’s how we’re making a heartfelt difference: - We are at the forefront of scientific collaboration, focusing on novel diagnostic technologies and treatments to target resistant bacteria. - By driving coordinated action with a broad range of partners, we are tackling AMR from multiple fronts and ensuring a unified response. - By working together to improve patients' access to the latest innovations. Through these efforts, Roche is dedicated to preserving the effectiveness of antibiotics and safeguarding global health for future generations. Click here to learn more: https://lnkd.in/dWnC_pf7 #AMR #AntibioticResistance #RocheAMR
-
Imagine a world where diagnosing complex health conditions is more efficient than ever before: Next-generation sequencing (NGS) is a potent tool for tackling unanswered healthcare questions. As excitement for NGS grows, Roche has responded to the demand for greater speed and accuracy by creating an entirely new class of NGS: sequencing by expansion (SBX). SBX technology paves the way for scientists to address today’s most urgent and complex health challenges, while bringing to light solutions for current questions and new insights that will shape the future of healthcare. Ready to learn more about SBX and its impact? https://lnkd.in/dPEh6Pxb #Genomics #NGS #MakeSpaceWithSBX #RocheSBX
-
Discover Susagna Padrissa Altes' journey of curiosity and resilience. As a child, she often felt out of place, searching for a space where she could truly belong. That space revealed itself in the realm of starting her career at Roche and using her passion for science along with her skills to build community and help people coming together, allowing them to thrive to build a healthier future for everyone and generations to come. 🌟Let’s build a healthier future, together. Start your journey with us. Learn more: https://lnkd.in/d-Rg_Y6d https://lnkd.in/d77ZE5Hw
Finding Belonging in Science: Susagna's Journey
https://www.youtube.com/
-
To accelerate innovation in human biology, researchers at the Institute of Human Biology (IHB), ETH Zürich, Helmholtz Munich, and global partners have created the first comprehensive #organoid atlases for the brain, lung, and intestine. Organoids – lab-grown 3D complex tissue cultures derived from stem cells – are transforming how we model human disease. But until now, differences in lab protocols made it hard to compare results across studies. With this new open-access resource, researchers can now integrate datasets, benchmark organoids across labs, and compare them directly to patient tissues.This pioneering work sets a new standard for reproducibility and collaboration in the field. Read more here: https://spkl.io/6042f2bFe
-
-
📢 We need your voice! Roche, as a member of the Sustainable Markets Initiative, is collaborating with ten other pharmaceutical companies to establish a worldwide standard – PAS 2090 – for measuring the environmental impact of our medicines. This will create a level playing field to track how green our products are, from start to finish. This will help us make smarter choices for the environment, leading to more eco-friendly meds and packaging down the line. Experts are currently asking for feedback to shape this standard, so if you're interested in building a more sustainable pharma world, now's your chance to have a say until 10 June! Check it out: https://spkl.io/6040fF4H8
-
-
How might we unleash the potential of digital solutions in cardiovascular and emergency care? In the last episode of Cardio Insights hosted by Mathieu Chaffard, we hear from Dr. Matthew Prime from Roche Diagnostics, diving into the current challenges that hospitals and health systems face globally, and how innovation might be driven collaboratively between public and private actors to move digital solutions forward. Based on his experience as a clinician and business leader, Dr. Prime shares his views on key success criteria to deliver impactful digital solutions for health systems, the constraints that need to be acknowledged, and some of the greatest breakthroughs he has witnessed through working with leading hospitals and institutions across the globe. Cardio Insights is a podcast produced by Roche, exploring how digital solutions are transforming cardiovascular and emergency medicine! Tune in to this episode today on Spotify, Apple Podcasts, and YouTube: https://spkl.io/6048f0CjC
Verbundene Seiten
Ähnliche Seiten
Finanzierung
Roche
Insgesamt 4 Finanzierungsrunden
![]()
SoftBank
Weitere Informationen auf Crunchbase
Letzte Runde
Kapitalerhöhung nach Börsengang
Externer Crunchbase-Link für die letzte Finanzierungsrunde
5.000.000.000,00 $
Investor:innen